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Background: The absence of a survival benefit for whole brain radiotherapy (WBRT) among randomized trials has been
attributed to a competing risk of death from extracranial disease. We re-analyzed EORTC 22952 to assess the impact of WBRT on
survival for patients with controlled extracranial disease or favorable prognoses.
Patients and methods: We utilized Cox regression, landmark analysis, and the Kaplan–Meier method to evaluate the impact
of WBRT on survival accounting for (i) extracranial progression as a time-dependent covariate in all patients and (ii) diagnosis-
specific graded prognostic assessment (GPA) score in patients with primary non-small-cell lung cancer (NSCLC).
Results: A total of 329 patients treated per-protocol were included for analysis with a median follow up of 26months. One
hundred and fifteen (35%) patients had no extracranial progression; 70 (21%) patients had progression<90 days, 65 (20%)
between 90 and 180 days, and 79 (24%) patients>180 days from randomization. There was no difference in the model-based
risk of death in the WBRT group before [hazard ratio (HR) (95% CI)¼0.70 (0.45–1.11), P¼ 0.133), or after [HR (95% CI)¼1.20
(0.89–1.61), P¼ 0.214] extracranial progression. Among 177 patients with NSCLC, 175 had data available for GPA calculation.
There was no significant survival benefit to WBRT among NSCLC patients with favorable GPA scores [HR (95% CI)¼1.10
(0.68–1.79)] or unfavorable GPA scores [HR (95% CI)¼1.11 (0.71–1.76)].
Conclusions: Among patients with limited extracranial disease and one to three brain metastases at enrollment, we found no
significant survival benefit to WBRT among NSCLC patients with favorable GPA scores or patients with any histology and
controlled extracranial disease status. This exploratory analysis of phase III data supports the practice of omitting WBRT for
patients with limited brain metastases undergoing SRS and close surveillance.
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Introduction
Whole brain radiotherapy (WBRT) administered in addition to
neurosurgery or stereotactic radiosurgery (SRS) consistently led
to improved intracranial control of metastatic brain disease in
randomized controlled trials but without an associated overall
survival (OS) benefit [1–5]. Both the efficacy of salvage therapy
and the competing risk of death from extracranial disease have
been put forward to explain this observation [5, 6].
The relative importance of these two factors has significant
clinical implications. If there were perfect salvage therapy, up-
front WBRT would never be indicated in addition to SRS or sur-
gery for patients with limited metastases. If, however, competing
risk from systemic disease is the prime factor that decouples im-
proved intracranial control and OS, then there may be a patient
population with limited competing systemic risk that would
benefit from WBRT. In fact, re-analysis of a prior randomized
trial of SRS with or without WBRT suggested such an OS benefit
from WBRT for patients with good prognostic grading [6].
The European Organization for Research and Treatment of
Cancer (EORTC) 22952-26001 study is the largest prospective
trial of SRS or neurosurgery with or without WBRT in the setting
of limited brain metastases, finding no impact of WBRT on OS
[4]. Furthermore, EORTC 22952 was unique in requiring stable
extracranial disease or brain only metastases at enrollment, and is
thus enriched for patients with a potentially reduced risk of death
from non-CNS causes at enrollment [4]. While this population
with seemingly low competing risk from systemic disease had no
benefit in the overall population, we re-analyzed EORTC 22952
to determine whether WBRT improved OS for patients with con-
trolled extracranial disease following treatment and for patients
with favorable prognostic factors.
Methods–patients
Study design
This is an unplanned secondary analysis of the phase III EORTC 22952-
26001 trial which randomized patients with one to three brain metastases
with stable systemic disease or asymptomatic primary tumors with brain
only metastasis to adjuvant WBRT or observation after SRS or surgical re-
section [4]. Eligibility criteria included patients aged 18 years or older,
WHO performance status2 at baseline, one to three brain metastases,
and stable systemic cancer for 3 months or asymptomatic synchronous pri-
mary tumor without metastases outside the CNS. Maximum tumor sizes
were 3.5 cm for single and 2.5 cm for multiple metastases. The original
protocol was approved by ethics committees at participating institutions
and all patients provided written informed consent. This secondary ana-
lysis was approved by the EORTC and the Fox Chase Cancer Center insti-
tutional review board.
Intervention
WBRT was administered to 30 Gy in 10 fractions. SRS was prescribed to
25 Gy at the center of the metastases, with a minimum dose of 20 Gy to
the surface of the planning target volume (1–2 mm margin in addition to
gross tumor volume). Patients undergoing SRS completed a short steroid
taper around the time of their procedure. Surgical patients underwent
complete resection with the extent of resection assessed similarly for all
patients of a single institution. CT/MRI were strongly recommended.
Statistical analysis
Baseline characteristics of patients were compared across treatment arms
using Chi-squared tests. The primary analysis population was defined as
‘as treated per-protocol’, i.e. patients who actually received/did not re-
ceive WBRT in accordance with their randomly assigned treatment (sup-
plementary Figure S1, available at Annals of Oncology online). In
secondary analyses, we also considered ‘as treated’ and ‘intent to treat’
populations; analyses and definitions of populations are listed in the sup-
plementary data, available at Annals of Oncology online. We used
Kaplan–Meier curves to estimate survival functions in patient groups
defined by receipt of WBRT, and compared survival between groups
using log-rank tests. We used Cox proportional hazards regression to ad-
just for important patient factors. We included time to extracranial pro-
gression as a time-dependent covariate, and estimated hazard ratios
(HRs) for WBRT both before and after extracranial progression.
For context, we also created cumulative incidence curves for extracranial
progression in a competing risks framework. We further carried out a
landmark analysis, examining survival in the subset of patients who sur-
vived without extracranial progression to at least 6 months. Diagnosis-
specific GPA values were calculated for patients with non-small-cell lung
cancer (NSCLC) and dichotomized as favorable (GPA 2.5–4.0) or un-
favorable (GPA 0.5–2.0) prognoses to analyze the relationship of progno-
sis and WBRT and to compare results with prior studies [6]. For the GPA
calculation, we considered the following performance status conversion:
ECOG/WHO 0¼KPS 90%–100%, ECOG/WHO 1¼KPS 70–80, and
ECOG/WHO 2¼KPS< 70 [7]. Statistical significance was defined as
P< 0.05. Analyses were carried out using SAS (version 9.4) and Stata
(version 12.1) statistical software.
Results
Overall, a total of 329 patients were included in the analysis (sup-
plementary Figure S1, available at Annals of Oncology online).
The median follow-up among living patients was 26 months.
Baseline patient characteristics reflected the original publication
(Table 1) [4]. A total of 115 (35%) patients had no extracranial
progression during study follow-up, while 70 (21%) patients had
extracranial progression<90 days, 65 (20%) between 90 and 180
days, and 79 (24%) patients>180 days.
A total of 175 NSCLC patients had data available for GPA cal-
culation; 101 (58%) had favorable diagnosis-specific GPA scores.
The distribution of GPA among NSCLC patients was 3.5–4.0
(13), 2.5–3.0 (88), 1.5–2.0 (65), and 0.5–1.0 (9). Baseline patient
characteristics for NSCLC patients stratified by GPA are listed in
supplementary Table S1, available at Annals of Oncology online.
Time to extracranial progression
There was no significant difference in time to extracranial pro-
gression according to the receipt of WBRT (supplementary
Figure S2, available at Annals of Oncology online). OS according
to receipt of WBRT before extracranial progression yielded simi-
lar estimates of survival in the two groups (Figure 1A). In the
model-based risk of death, WBRT was not statistically signifi-
cantly associated with mortality either before extracranial pro-
gression [HR¼ 0.70, 95% CI¼ (0.45, 1.11)] or following
extracranial progression [HR¼ 1.20, 95% CI¼ (0.89, 1.61)]
(Table 2). Baseline patient characteristics of the intention to treat
and as treated analyses are listed in supplementary Tables S2 and
S5, available at Annals of Oncology online, respectively.
Unadjusted OS in the intention to treat and as treated analyses
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produced findings similar to the per-protocol analysis (supple-
mentary Figures S3 and S5, available at Annals of Oncology on-
line). Model-based risk of death for WBRT did not differ
significantly either before extracranial progression or following
extracranial progression in intention to treat (supplementary
Table S3, available at Annals of Oncology online) or as treated
(supplementary Table S6, available at Annals of Oncology online)
populations.
Landmark analysis
The time to systemic progression with death as a competing risk
(i.e. the cumulative incidence of systemic progression over time)
is shown in supplementary Figure S2, available at Annals of
Oncology online. The impact of WBRT on OS for patients with
controlled systemic disease at 6 months (landmark) following
randomization is shown in Figure 1B. Patients who died within
6 months following randomization were excluded to limit bias.
There was no impact of WBRT on survival among patients with
controlled disease at 6 months (P¼ 0.51).
NSCLC diagnosis-specific GPA
OS did not vary according to the use of WBRT in NSCLC patients
with either favorable or unfavorable GPA scores (Table 3; Figure
2) in the per-protocol analysis. Analysis according to intention to
treat (supplementary Table S4 and Figure S4, available at Annals
of Oncology online) and as treated (supplementary Table S7 and
Figure S6, available at Annals of Oncology online) showed similar
findings.
Discussion
No phase III randomized trial has demonstrated that the im-
proved intracranial control resulting from the addition of WBRT
to SRS or surgery for patients with limited brain metastases trans-
lates into a survival benefit. One potential reason for this discon-
nect may be the competing risk of death from systemic disease,
which may dilute or eliminate any benefit from WBRT [5, 6]. If
progressive systemic disease leads to death before intracranial
progression, improving intracranial control would not have any
effect on survival. Even in cases where intracranial progression
would have been the proximal cause of death, if systemic disease
is progressive on a similar time scale, improved intracranial con-
trol might merely trade one cause of death for another or provide
only marginal benefit that might be diluted in a population.
Furthermore, salvage therapy need not be perfect; rather it only
requires extending the time line of intracranial progression be-
yond that of systemic disease in order to have no demonstrated
benefit from improved initial CNS control or quality of life.
WBRT treats the possibility of microscopic disease, marginally
improves control of known disease in addition to local therapy,
and may not address future metastatic disease to the brain. Thus
the risk of death from systemic progression must be relatively low
compared with that of microscopic CNS disease in order to de-
rive a benefit from WBRT. Though the diagnosis of brain metas-
tasis is frequently perceived as the portent of a grim prognosis,
systemic disease status and its response to therapy is typically the
driver of mortality [8, 9]. Retrospective analyses have shown that
the risk of extracranial disease progression is a major prognostic
factor [10, 11]. In fact, the Radiation Therapy Oncology Group
(RTOG) recursive partitioning analysis (RPA) prognostic index,
derived from pooled RTOG trial data in brain metastases, had
two of four prognostic factors (controlled primary and brain only
metastases) related to risk from systemic progressive disease [12].
While several other randomized studies showed no survival
benefit from the addition of WBRT to ablative local therapy in
oligometastatic disease, the EORTC 22952 was unique in allow-
ing only patients with no evidence of progressive extracranial dis-
ease on study. While this eligibility criterion may have
constituted an ideal population from which to isolate a survival
signal from WBRT given the hypothetically decreased risk from
systemic disease, no improved survival was seen with increased
intracranial control [4]. In fact, in spite of the restrictive eligibility
criterion, 40% of patients experienced extracranial progression
by 6 months. We hypothesized that if the patients that were truly
at low risk for disease progression could be identified, perhaps a
benefit from WBRT would be discovered. In order to answer this
question, we conducted a landmark analysis for patients that had
not progressed by 6 months, intending to identify factors that
predicted systemic stability should there have been a benefit to
WBRT in that group. But instead we found no improved survival
for patients that had not progressed systemically. There was no
difference in risk of death related to WBRT before extracranial
progression nor was WBRT associated with survival after
Table 1. Baseline patient characteristics according to per-protocol receipt
of whole brain radiotherapy (WBRT)
No WBRT WBRT P
Age (median) 60.0 60.6 0.30
Local therapy
Complete surgery 78 77 0.95
Radiosurgery 87 87
ECOG performance status
0 77 65 0.44
1 71 80
2 17 19
Primary site
Breast 16 17 0.94
Colo-rectum 15 14
Kidney 13 16
Lung 88 89
Melanoma 7 8
Other/unknown 26 20
Number of metastases
1 131 133 0.93
2 25 23
3 9 8
Macroscopic tumor outside brain
Absent 80 75 0.87
Present 78 81
Unknown 7 8
Extracranial progression
No 60 55 0.59
Yes 105 109
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progression of ECD (HR¼ 0.70, P¼ 0.133; HR¼ 1.20,
P¼ 0.214, respectively).
Perhaps extracranial disease is not the only factor that may
interact with a potential benefit from WBRT and patients with
other good prognostic factors might benefit. Aoyama et al.
showed in a post hoc analysis of the JROSG 99-1 trial that there
was longer survival associated with WBRT for patients with
NSCLC and a favorable graded prognostic assessment (GPA)
score (2.5–4.0) at diagnosis but not for those with a poor GPA.
The GPA is a more contemporary prognostic index that reflects
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Figure 1. (A) Overall survival (OS) according to receipt of whole brain radiotherapy before extracranial progression (per-protocol analysis).
Patients were censored at the time of follow up or extracranial progression. Thus, this plot displays the survival effect of WBRT among
patients without evidence of extracranial progression (estimated from all patients, using their extracranial progression free interval).
(B) Landmark analysis of OS according to the receipt of whole brain radiotherapy (WBRT). The landmark represented the absence of extracra-
nial progression at 6months. Patients with events before 6months were excluded from analysis.
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the heterogeneity in survival between and within primary cancers
better than RPA [13]. In addition to extracranial disease status,
age, performance status, and number of brain metastases factor
in to the NSCLC GPA used in re-analysis.
Contrary to the JROSG re-analysis, however, we found no sur-
vival associations with WBRT for NSCLC cancer patients with a
favorable GPA at time of randomization (Table 3; Figure 2).
Again, replicating the analysis in the intention to treat and as
treated populations yielded similar estimates (supplementary
Tables S4 and S7, available at Annals of Oncology online,
respectively).
There are several possible reasons for these discordant findings.
The original EORTC 22952 trial was not powered to detect an OS
difference. Sample size was small in both our unplanned analysis
(n¼ 101) and the JROSG secondary analysis (n¼ 47). We con-
sidered the possibility that the current analysis may lack power
and constitute a type II error. Because post hoc power calcula-
tions are flawed [14], we directly compared the estimates of bene-
fit for the two analyses. The JROSG analysis reported an
increased risk of death for patients with DS-GPA>2.5 who did
not receive WBRT, with an HR of 1.92, which is equivalent to an
HR of 0.52 for receipt of WBRT. This magnitude of benefit from
WBRT was outside of the lower bound 95% confidence interval
of our estimate [HR (95% CI)¼ 1.11 (0.71–1.76)] among the
comparable favorable DS-GPA patient group. In fact the HR for
death in our population was slightly over 1, a non-significant
trend towards a detriment with WBRT. Therefore, while a false
negative error certainly remains a possibility in our analysis, a
large benefit with a similar magnitude to that seen in the JROSG
study is unlikely.
Differences in the populations studied and the biology of disease
may also play a role in the discordant findings. JROSG 99-1
included patients from a consortium of 11 Japanese centers. The
biologic heterogeneity of NSCLC cancer between Asian and non-
Asian populations has been well documented, specifically in the in-
cidence of epidermal growth factor receptor (EGFR) tyrosine kinase
mutations [15]. It is conceivable that the ability to detect a survival
benefit from WBRT among patients with NSCLC and a favorable
GPA in JROSG-99-1 reflects an enriched population of EFGR-
mutated cancers with different patterns of failure and responses to
systemic therapy, which in turn permit superior upfront detection
of patients who will benefit from WBRT. That is, biologic differ-
ences may account for an actual survival benefit seen for WBRT in
the Japanese analysis but not in the European one. Perhaps the tran-
sition to a molecularly driven lung-specific GPA (Lung-molGPA)
[16, 17] would have helped normalize the differences between the
JROSG and our study. While our model-based analysis using pro-
gression of extracranial disease as a time-dependent covariate and
landmark analysis may mitigate some differences between the
populations in terms of risk of systemic progression, the availability
of and response to systemic therapy after progression for EGFRmu-
tant tumors is not accounted for in this analysis.
Finally, the results of either or both analyses may be a product
of the limitations of secondary analyses. In short, they are ex-
ploratory and not designed to definitively answer the hypothesis
in question. Further investigation into populations that may
benefit from the upfront delivery of WBRT might include tumor
molecular factors as well as other clinical factors such as the risk
for leptomeningeal disease [18–22].
Conclusion
Our secondary analysis of EORTC 22952-26001 found no associ-
ation of WBRT with improved survival, regardless of the compet-
ing risk from systemic disease progression and regardless of
favorable prognostic factors in NSCLC. These results are discord-
ant with another secondary analysis; further investigations are
warranted to elucidate possible subgroups that might benefit
from aggressive intracranial control.
Table 2. Cox regression analysis of overall survival according to per-proto-
col receipt of whole brain radiotherapy
Parameter Hazard
ratio
[95% CI] P
Whole brain radiotherapya
Before extracranial progression 0.70 [0.45–1.11] 0.133
After extracranial progression 1.20 [0.89–1.61] 0.214
Age (continuous) 1.02 [1.01–1.04] <0.001
Extracranial progression 4.51 [3.03–6.72] <0.001
Local therapy
Radiosurgery 1.00 Referent –
Surgery 0.86 [0.66–1.14] 0.293
ECOG performance status
0 1.00 Referent –
1 1.08 [0.83–1.40] 0.571
2 1.70 [1.13–2.55] 0.011
Primary site lung (versus other) 1.32 [1.02–1.70] 0.033
Number of metastases (2–3 versus 1) 1.09 [0.79–1.49] 0.609
Macroscopic tumor present outside brain
Absent 1.00 Referent –
Present 1.10 [0.84–1.44] 0.490
Unknown 1.64 [0.83–3.24] 0.154
Extracranial progression was included as a time-dependent covariate.
aReference group¼ arms randomized to no whole brain radiotherapy.
Table 3. Cox regression analysis of overall survival according to the per-
protocol receipt of whole brain radiotherapy and diagnosis-specific
graded prognostic assessment score for lung cancer patients
Parameter Hazard ratio [95% CI] P
Whole brain radiotherapya
GPA <2.5 1.10 [0.68–1.79] 0.690
GPA 2.5 1.11 [0.71–1.76] 0.641
Local therapy
Radiosurgery 1.00 Referent –
Surgery 0.96 [0.69–1.35] 0.828
GPA 2.5 0.64 [0.40–1.03] 0.067
aReference group¼ arms randomized to no whole brain radiotherapy
and treated per-protocol.
Original article Annals of Oncology
2592 | Churilla et al. Volume 28 | Issue 10 | 2017
Downloaded from https://academic.oup.com/annonc/article-abstract/28/10/2588/3894530
by University of Torino user
on 11 January 2018
Acknowledgement
The authors would like to thank the European Organization for
Research and Treatment of Cancer for collaboration and sharing
of trial data to perform this analysis.
Funding
This publication was supported by grant number P30
CA006927 from the National Cancer Institute and National
Institutes of Health. Its contents are solely the responsibility of
the authors and do not necessarily represent the official views of
the National Cancer Institute or the National Institutes of
Health. The contributions of SC and LC (EORTC
Headquarters) to this publication were supported by Fonds
Cancer (FOCA) (no grant numbers apply) from Belgium.
Disclosure
The authors have declared no conflicts of interest relevant to
this work. Disclosures outside of this work include: EH: research
funding through Pfizer, paid to institution; AA: funding from
Varian Medical Systems; BA: consulting relationship with
Abbvie, BMS, Precision Health Economics, and Schlesinger
Associates.
References
1. Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in
the treatment of single metastases to the brain: a randomized trial. JAMA
1998; 280(17): 1485–1489.
2. Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus
whole-brain radiation therapy vs stereotactic radiosurgery alone for
treatment of brain metastases: a randomized controlled trial. JAMA
2006; 295(21): 2483–2491.
3. Chang EL, Wefel JS, Hess KR et al. Neurocognition in patients with brain
metastases treated with radiosurgery or radiosurgery plus whole-brain ir-
radiation: a randomised controlled trial. Lancet Oncol 2009; 10(11):
1037–1044.
4. Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radio-
therapy versus observation after radiosurgery or surgical resection of one
to three cerebral metastases: results of the EORTC 22952-26001 study.
J Clin Oncol 2011; 29(2): 134–141.
5. Brown PD, Jaeckle K, Ballman KV et al. Effect of radiosurgery alone vs
radiosurgery with whole brain radiation therapy on cognitive function in
patients with 1 to 3 brain metastases. A Randomized Clinical Trial.
JAMA 2016; 316(4): 401–409.
6. Aoyama H, Tago M, Shirato H; Japanese Radiation Oncology Study
Group 99-1 (JROSG 99-1) Investigators. Stereotactic radiosurgery with
or without whole-brain radiotherapy for brain metastases: secondary
analysis of the JROSG 99-1 Randomized Clinical Trial. JAMA Oncol
2015; 1(4): 457–464.
7. ECOG Performance Status. http://ecog-acrin.org/resources/ecog-per
formance-status (20 March 2017, date last accessed).
8. Kondziolka D, Parry PV, Lunsford LD et al. The accuracy of predicting
survival in individual patients with cancer. J Neurosurg 2014; 120(1):
24–30.
9. Lin NU, Claus E, Sohl J et al. Sites of distant recurrence and clinical outcomes
in patients with metastatic triple-negative breast cancer: high incidence of
central nervous system metastases. Cancer 2008; 113(10): 2638–2645.
10. Dyer MA, Kelly PJ, Chen Y-H et al. Importance of extracranial disease status
and tumor subtype for patients undergoing radiosurgery for breast cancer
brain metastases. Int J Radiat Oncol Biol Phys 2012; 83(4): e479–e486.
11. Dyer MA, Arvold ND, Chen Y-H et al. The role of whole brain radiation
therapy in the management of melanoma brain metastases. Radiat Oncol
Lond Engl 2014; 9: 143.
12. Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA)
of prognostic factors in three Radiation Therapy Oncology Group
100
75
50
O
ve
ra
ll 
su
rv
iva
l (%
)
25
0
0
No WBRT, GPA<2.5
No WBRT, GPA>=2.5
WBRT, GPA<2.5
WBRT, GPA>=2.5
12
Number at risk
37 13 3 3
3
0
0
0
0
0
0
0
0
0
0
0
0
9 4
1
1
1
1
2
5
12
13
24
20
37
50
51
24 36 48
Time (months)
60 72 84
No WBRT, GPA<2.5 No WBRT, GPA>=2.5
WBRT, GPA<2.5 WBRT, GPA>=2.5
Figure 2. Overall survival among non-small-cell lung cancer (NSCLC) patients according to receipt of whole brain radiotherapy stratified by
diagnosis-specific Graded Prognostic Assessment (GPA) score (per-protocol). NSCLC patients (n¼ 175) were stratified according to GPA
scores of<2.5 (unfavorable) and2.5 (favorable).
Annals of Oncology Original article
Volume 28 | Issue 10 | 2017 doi:10.1093/annonc/mdx332 | 2593
Downloaded from https://academic.oup.com/annonc/article-abstract/28/10/2588/3894530
by University of Torino user
on 11 January 2018
(RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys 1997;
37(4): 745–751.
13. Sperduto PW, Berkey B, Gaspar LE et al. A new prognostic index and
comparison to three other indices for patients with brain metastases: an
analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol
Phys 2008; 70(2): 510–514.
14. Hoenig JM, Heisey DM. The abuse of power. Am Stat 2001; 55(1):
19–24.
15. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-
small-cell lung cancer of adenocarcinoma histology: a systematic review
and global map by ethnicity (mutMapII). Am J Cancer Res 2015; 5(9):
2892–2911.
16. Sperduto PW, Yang TJ, Beal K et al. The effect of gene alterations and
tyrosine kinase inhibition on survival and cause of death in patients with
adenocarcinoma of the lung and brain metastases. Int J Radiat Oncol
Biol Phys 2016; 96(2): 406–413.
17. Sperduto PW, Yang TJ, Beal K et al. Estimating survival in patients with
lung cancer and brain metastases: an update of the graded prognostic
assessment for lung cancer using molecular markers (Lung-molGPA).
JAMA Oncol 2017; 3(6): 827–831.
18. van der Ree TC, Dippel DW, Avezaat CJ et al. Leptomeningeal metastasis
after surgical resection of brain metastases. J Neurol Neurosurg
Psychiatry 1999; 66(2): 225–227.
19. Ahn JH, Lee SH, Kim S et al. Risk for leptomeningeal seeding after resec-
tion for brain metastases: implication of tumor location with mode of re-
section. J Neurosurg 2012; 116(5): 984–993.
20. Atalar B, Modlin LA, Choi CYH et al. Risk of leptomeningeal disease
in patients treated with stereotactic radiosurgery targeting the postopera-
tive resection cavity for brain metastases. JAMA Oncol 2013; 87(4):
713–718.
21. Brennan C, Yang TJ, Hilden P et al. A phase 2 trial of stereotactic radio-
surgery boost after surgical resection for brain metastases. JAMA Oncol
2014; 88(1): 130–136.
22. Trifiletti DM, Romano KD, Xu Z et al. Leptomeningeal disease following
stereotactic radiosurgery for brain metastases from breast cancer.
J Neurooncol 2015; 124(3): 421–427.
Original article Annals of Oncology
2594 | Churilla et al. Volume 28 | Issue 10 | 2017
Downloaded from https://academic.oup.com/annonc/article-abstract/28/10/2588/3894530
by University of Torino user
on 11 January 2018
